Developing Arbaclofen for Fragile X – Dr. Mark Bear 1:1 with FRAXA

December 9, 2020

MIT professor Dr. Mark Bear founded Allos Pharma to develop arbaclofen (STX209) as a treatment for Fragile X syndrome. Dr. Bear sat down with FRAXA co-founder Katie Clapp to share the story and next steps.

Read More »

Yale Researcher Dr. Elizabeth Jonas 1:1 with FRAXA

September 18, 2020

We talk with Dr. Elizabeth Jonas at Yale School of Medicine about her new research suggesting that leaky mitochondria which may be involved in Parkinson’s and Fragile X syndrome.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)